Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5927783 | American Heart Journal | 2014 | 9 Pages |
Abstract
Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Rury R. FRCP, Mary A. MD, Juliana C.N. MD, Jean-Louis MD, Zoë RN, Junbo MD, Hertzel MD, MSc, Yong MD, John J. MD, Lars MD, PhD, Winitha MSc, Stefan PhD, Michal MD, Michael J. MD PhD, Jaakko MD, MA, PhD, Wenying MD, Dayi MD, Changyu MD,